Private Equity and the Medical Practice

Why the structure exists

Begin with the constraint, because everything downstream is shaped by it. Business and Professions Code section 2408 requires each shareholder, director and officer of a medical corporation — other than an assistant secretary or assistant treasurer — to be a licensed person, subject to the narrow multidisciplinary allowance in Corporations Code section 13401.5. That allowance admits a listed set of allied licensees up to 49 per cent of shares. It admits no unlicensed person at any percentage.

An investor therefore cannot buy the thing that ordinarily gets bought. It cannot hold equity in the operating company, cannot sit on its board, cannot appoint its officers, and cannot vote its shares. Every instrument by which capital normally secures a return on a services business is closed off at the entity that holds the customer relationship.

What remains is contract. The response the market settled on splits the enterprise in two. A professional corporation — owned by one or more licensed physicians, frequently a single physician — holds the licence, employs the clinicians, contracts with payers and bills for professional services. A separate management services organisation, owned by the investor, holds substantially everything else: the premises or the lease, the equipment, the information systems, the brand, the non-clinical workforce, the revenue-cycle function, and the capital. A management services agreement binds the two, under which the MSO provides services to the professional corporation for a fee.

Stated at that level the arrangement is unremarkable and lawful. Practices have bought administrative services from third parties for as long as there have been practices, and nothing in California law requires a physician to own their own billing department. The Medical Board’s objection has never been to the existence of a management company. It is to what the management agreement, read honestly, actually allocates.

Where the money is

The economics deserve to be stated plainly, because they are what the legal analysis is about. The professional corporation collects the professional fees. The management fee then moves the great majority of the resulting margin to the MSO, and the investor’s return is that fee stream and the enterprise value built on it. The physician shareholder of the professional corporation typically holds shares worth very little relative to the enterprise, because the enterprise value has been contracted into the other entity.

That is the design working as intended, and it is why the ownership rule does so little economic work on its own. Section 2408 guarantees that a licensed person holds the shares. It does not guarantee that the shares are worth anything, and it does not prevent the value of the practice from accruing to someone who may not hold them.

The friendly shareholder and the instrument nobody reads

One document does more structural work than the management agreement and receives a fraction of the attention. The physician who holds the professional corporation’s shares is generally required to sign a stock transfer restriction agreement — variously a succession agreement, a shareholder agreement, or a transfer restriction agreement — under which the shares cannot be sold, transferred, encumbered or voted without the MSO’s consent, and under which the physician can be required to transfer the shares to another licensed person nominated by the MSO on stated triggers.

The purpose is straightforward: it makes the investor’s position durable against the possibility that the nominal owner leaves, dies, is disciplined, or changes their mind. Without it, the investor’s entire structure depends on the continued goodwill of one individual.

It is also the clause that most directly answers the question the doctrine actually asks. If the licensed shareholder cannot vote their shares without permission and can be compelled to hand them to a person the investor selects, the professional powers that section 2400 reserves to licensed persons have in substance been transferred to an entity that cannot hold them. The Medical Board lists restricting the doctors from voting, selling or transferring their shares without the employing corporation’s permission among the indicators of unlawful corporate practice. This indicator is not a feature of unusually aggressive structures. It is close to universal.

The Attorney General has now enjoined this specific mechanism

The transfer restriction agreement stopped being a theoretical exposure in 2026. In a settlement announced on 26 June 2026 with a healthcare technology company, its affiliated professional medical corporations and its co-founder and former chief executive, the California Attorney General obtained $4.5 million in combined penalties and a required reorganisation of the company’s friendly-PC arrangement.

The injunctive terms reach the deal mechanics directly. The defendants are permanently enjoined from having complete authority over advertising, payer negotiations, selection of medical equipment, and the hiring, firing and compensation of licensed medical professionals; from obtaining any ownership interest in a professional corporation, including through an assignable option agreement granting the management company the right to acquire that interest for its own account; and from entering revolving credit agreements requiring the affiliated professional corporations to seek financing exclusively from the management company at an above-market rate — with a carve-out permitting a first-priority lien on certain assets subject to conventional lender restrictions.

Three features of that list deserve attention from anyone holding or drafting these documents. The option agreement prohibition is the transfer-restriction mechanism described above, named and enjoined. The exclusive above-market financing prohibition reaches a term that is ordinarily presented as treasury management rather than control. And the co-founder was named personally — the settlement did not confine itself to entity liability.

Two earlier actions in the same period frame it. On 30 March 2026 the Attorney General filed an amicus curiae brief in Art Center Holdings, Inc. v. WCE CA Art, LLC, pending before the Second District Court of Appeal, urging affirmance of a trial-court holding that contractual provisions permitting a management services organisation to replace a practice’s physician-owner violate the corporate practice prohibition. On 7 May 2026 the office announced a settlement with a private-equity-owned dental support organisation over the corporate practice of dentistry and false advertising, for $2 million in penalties and $300,000 in patient restitution.

Their status should be stated precisely. An amicus brief is an advocacy position and binds nothing until the court rules; the appeal was pending when last verified. Both settlements were announced subject to court approval, and that approval was not verified as at 16 August 2026. The Carbon Health matter also proceeded against a company that had filed for Chapter 11 restructuring during the investigation. None of the three is a judicial construction of Division 1.7 — all rest on the pre-existing doctrine. What they establish is enforcement posture rather than new law, and the posture is that the office is reading past nominal professional ownership to the contractual mechanics underneath. The matters are tracked on the enforcement desk.

Whether the investor in front of you is even covered

Division 1.7 binds two defined categories, and a diligence exercise that assumes coverage will misread as many deals as one that assumes the opposite. Section 1190(b)(1) defines a private equity group as an investor or group of investors who primarily engage in the raising or returning of capital and who invest, develop, or dispose of specified assets. Section 1190(a)(1) defines a hedge fund as a pool of funds managed by investors for the purpose of earning a return on those funds, regardless of the strategies used to manage them, including pools managed or controlled by private limited partnerships.

Both definitions carve out passive money. A natural person or entity that contributes or promises to contribute funds, but otherwise does not participate in the management of the fund or group or its assets, or in any change in control, is excluded. The limited partner in a fund is not thereby a covered entity; the general partner and the management company are a different question. Both also exclude hospitals and hospital systems owning one or more licensed hospitals under Health and Safety Code section 1250(a) or (b), their affiliates as defined in Corporations Code section 150, and entities they manage or control — and public agencies as defined in Government Code section 6500, together with the clinics, outpatient settings, health facilities and ambulatory surgical centres they own, operate, manage, control or are affiliated with.

The consequence is a coverage map with a visible shape. A hospital system that acquires a physician group and manages it through a subsidiary is outside Division 1.7 entirely. A county health system is outside it. A sponsor-backed platform is inside it. The same operational conduct — the same management agreement, the same approval mechanics — therefore attracts the statute or not depending on who owns the management company. Whether that distinction is defensible is a policy question; that it is the enacted one is not in doubt.

One asymmetry between the two definitions is worth flagging in any financing. Entities that solely provide or manage debt financing secured in whole or in part by the assets of a health care facility — expressly including banks and credit unions, commercial real estate lenders, bond underwriters and trustees — are excluded from “hedge fund.” No corresponding clause appears in the definition of “private equity group.” A credit fund that both lends and holds equity is not obviously within the debt-financing carve-out, and is not obviously outside the private equity group definition either.

The statute follows the control chain

The prohibitions are not confined to the entity that signs. Section 1191(c)(1) reaches a private equity group or hedge fund or an entity controlled directly, in whole or in part, by one. Section 1191(d)(1) is drawn wider still, reaching any entity controlled directly or indirectly, in whole or in part, by a covered entity.

In the ordinary platform structure the counterparty to the management services agreement is not the fund. It is a management company several tiers below it, often with its own minority co-investors and management equity. The phrase “in whole or in part” forecloses the argument that partial ownership breaks the chain, and “indirectly” in subdivision (d) forecloses the argument that intermediate holding companies do. An MSO majority-owned by a platform holdco which is in turn sponsor-controlled is within the covenant prohibition on the face of the text.

What Division 1.7 changed inside the deal documents

The doctrinal content of Division 1.7 — the definitions, the two prohibition lists, the safe harbour, the enforcement provision — is set out on the corporate practice of medicine page. What follows is the transactional consequence, which is a different question and produces different answers.

Standard clauses became void clauses

Read section 1191(a)(2) beside the schedule of services in a conventional management services agreement. The statute forbids the covered entity from exercising control over, or being delegated the power to do: owning or determining the content of patient medical records; selecting, hiring or firing clinicians and allied staff based in whole or in part on clinical competency; setting the parameters for third-party payer contracting; making decisions regarding the coding and billing of procedures; and approving the selection of medical equipment and supplies.

Records custody, payer contracting, revenue cycle, staffing and capital equipment are not incidental services in these agreements. They are the services. An MSO that does not run the revenue cycle and does not hold the systems in which the records sit is not providing the product investors are buying.

Before 2026 those allocations were evidence — indicators a regulator might read as showing control, weighed against whatever the agreement recited about physician autonomy. Since 1 January 2026 a provision that gives a private equity group or hedge fund control over one of the listed powers is void, unenforceable and against public policy by force of section 1191(c)(2). That is a different kind of exposure. It does not require a Medical Board proceeding, an Attorney General action, or a finding of any kind. The clause simply does not bind, and whichever party was relying on it discovers this at the moment it matters.

The remedy is worth reading precisely: it operates on the provision, not on the instrument. A management agreement with several offending clauses is not a nullity. It is an agreement that has quietly lost the terms the investor priced, while every obligation running the other way remains enforceable.

The safe harbour tells you how to draft, and where you cannot

Section 1191(h) provides that the section does not prohibit an unlicensed person or entity from assisting, or consulting with, a practice with respect to the decisions and activities described in paragraph (2) of subdivision (a), provided the physician or dentist retains the ultimate responsibility for, or approval of, those decisions and activities.

For the paragraph (2) list this is a workable instruction. The MSO may build the coding policy, recommend the equipment, model the payer terms and run the process, provided the clinician holds the decision. The drafting move is to convert control rights into recommendation-plus-approval rights — and the practical question becomes whether the approval is real. An approval that must be exercised within two business days, that is deemed given on silence, and that is held by a physician whose shares the MSO controls under a transfer restriction agreement is an approval in form. Section 1191(b) already forecloses arguments from corporate form; there is little reason to expect a different reception for arguments from formal approval mechanics.

For the paragraph (1) list there is no safe harbour at all, and the omission is doing deliberate work. Nothing in Division 1.7 permits a covered entity to assist or consult on the professional-judgment matters, which expressly include determining how many patients a physician shall see in a given period of time and how many hours a physician shall work. Patient volume and schedule density are ordinarily treated as operational metrics, and they are the metrics through which a management platform delivers its returns. The Legislature classified them as professional judgment, and put them outside the mechanism by which every other power on the list can be made compliant.

The covenant ban reaches documents the physician never signed

Section 1191(d)(1) applies to any contract involving the management of a practice doing business in California by, or the sale of real estate or other assets owned by such a practice to, a covered entity or an entity controlled directly or indirectly, in whole or in part, by one. Competition and non-disparagement clauses in those instruments are void, unenforceable and against public policy. The provision, its two savings, and how it differs from the general rule in Business and Professions Code section 16600 are set out on restrictive covenants.

The transactional consequence is what belongs here, and it is a diligence point. The instruments section 1191(d) reaches are the management services agreement and the asset purchase agreement — entity-to-entity documents that the individual clinician is frequently not a party to and has never seen. A review scoped to employment templates, which is how covenant diligence is normally run, will not surface them. The clauses at risk are also the ones an investor relies on to protect the value it is buying: the restraint that keeps clinicians from leaving with the patient base, and the silence provision that keeps quality and revenue-strategy disputes out of public view.

For a practice being acquired, the practical question is therefore which document the covenant lives in rather than what it says. A restraint in the physician’s employment agreement is a section 16600 question. The same restraint in the management agreement is a section 1191(d) question, void by force of statute since 1 January 2026, and it may bind nobody while everyone continues to behave as though it does.

How a void clause actually gets tested

Section 1191(e) entitles the Attorney General to injunctive relief, other equitable remedies a court deems appropriate, and attorney’s fees and costs incurred in remedying a violation. That is the only enforcement mechanism the division names. It states no private right of action, and it creates no new ground of licensee discipline.

It would be a mistake to read that as meaning the statute operates only when the Attorney General acts. Voidness is not a remedy that requires an enforcer — it is a defence. Section 1191(c)(2) provides that any provision within a contract or other agreement that violates subdivision (a) is void, unenforceable, and against public policy, and section 1191(d)(2) says the same of an offending covenant. A party sued on such a provision can raise that in the ordinary course.

The realistic first tests of Division 1.7 are therefore likely to arrive sideways: a departing physician sued on a non-disparagement clause in a management agreement; an MSO seeking to enforce a term the practice has stopped honouring; a dispute over which entity was entitled to make a billing decision. In each the statute appears as an answer rather than a claim. That also means the case law will develop through contract litigation between commercial parties rather than through regulatory enforcement, and will accumulate in a less visible place than Medical Board decisions.

For the physician the practical asymmetry remains what it was before 2026. The entity’s exposure under Division 1.7 is civil and runs to the Attorney General. The physician’s exposure for participating in an unlawful structure continues to run through the Medical Practice Act — sections 2264 and 2286 — where aiding and abetting requires no showing of knowledge or intent. Division 1.7 improved the position of practices against their investors. It did not reduce anyone’s licence risk.

AB 1415: the transaction now has a gate

Assembly Bill 1415 (Bonta), Chapter 641 of the Statutes of 2025, was approved by the Governor and filed with the Secretary of State on 11 October 2025, effective 1 January 2026. It amended sections 127500.2, 127501 and 127507 of the Health and Safety Code and added section 127501.5, extending the Office of Health Care Affordability’s material change transaction regime to reach the entities that sit above the practice.

As amended, section 127507 requires a “noticing entity” to give OHCA written notice at least 90 days before entering into an agreement or transaction with a health care entity, a management services organisation, or an entity that controls one, where the transaction would sell, transfer, lease, exchange, option, encumber, convey or otherwise dispose of a material amount of the assets of the health care entity or MSO, or would transfer control, responsibility or governance of a material amount of its assets or operations. The categories of noticing entity are defined at section 127507(h)(1) to (h)(4). A management services organisation must give notice of a transaction of that kind even where its counterparty is not itself a noticing entity.

Newly added section 127501.5 is separate and continuing: the office shall, in a manner it prescribes, establish requirements for management services organisations to submit data and other information as necessary to carry out its functions. That is a reporting obligation attaching to the MSO as an ongoing matter, not only at the point of a transaction.

The practical significance is not penalty exposure. It is visibility and timing. A regime that requires notice 90 days before closing converts a private reorganisation into a filed transaction with a waiting period, and it does so at the MSO layer — precisely where these deals were previously structured to sit outside state review.

Regulatory status, stated as it stands

The implementing regulations are not settled, and the page should not pretend otherwise. OHCA’s published frequently asked questions on AB 1415 state that notice obligations apply now: until regulations are enacted specifying the information required, noticing entities must provide at a minimum written notice of the transaction under section 127507(c)(2)(A), citing the noticing-entity definitions at section 127507(h)(1) to (h)(4). The FAQ records that existing statute and regulation require health care entities that are a party to or the subject of a transaction to file at least 90 days before the closing date, under section 127507(c)(2) and title 22, California Code of Regulations, section 97435(a), and that the office intends to establish the same filing timelines for noticing entities.

OHCA published proposed emergency regulatory text implementing AB 1415 on 15 May 2026, and the emergency route matters to the timetable: an emergency rulemaking package approved by the Office of Administrative Law takes effect on approval rather than after the ordinary rulemaking cycle, and OHCA’s existing material-change regulations were adopted the same way. The informal comment period closed on 11 June 2026 and the office discussed the draft at its board meeting on 24 June 2026, with the final proposed text expected to be submitted to the Office of Administrative Law in July 2026 and the regulations expected to take effect in August.

As at 16 August 2026 that approval could not be verified. No record of the Office of Administrative Law approving the AB 1415 package appears in the material checked for this page, and the most recent reporting located still describes the regulations as expected rather than in force. Anyone timing a transaction against this regime needs the current status confirmed directly with the office rather than taken from any secondary account, including this one.

The gap does not suspend the statute. AB 1415 has been in effect since 1 January 2026, and OHCA’s published guidance states that pending regulations noticing entities must provide at a minimum written notice under section 127507(c)(2)(A). A party closing a transaction now is subject to the notice obligation whether or not the implementing detail has been settled.

Exit, and the terms that were priced

The event these structures are built for is the exit, and it is where the 2026 changes compound. A sponsor selling a platform is selling contracted cash flows and the durability of the arrangements that produce them. Two of the mechanisms that made those arrangements durable — control over the operating decisions listed in section 1191(a)(2), and covenants restraining clinicians from competing or commenting — are now void as against a covered entity.

A secondary sale from one sponsor to another does not cure that: the buyer is also a covered entity, and section 1191(d)(1) reaches the sale of assets owned by the practice to such a buyer directly. The transaction is separately within the amended section 127507 notice regime, and section 127501.5 attaches continuing data obligations to the management services organisation itself.

None of that prevents an exit. It changes what is being sold, and it puts a state filing and a waiting period in front of a class of transaction that previously closed privately.

What the two statutes do not do

Neither instrument makes private-equity ownership of a California medical practice lawful, and reading them as a compliance pathway inverts them.

Section 1191(g) states that the section does not narrow, abrogate, or otherwise lower the bar on the corporate practice of medicine or dentistry as set forth in the Business and Professions Code or the Corporations Code, or any other applicable state or federal law. Division 1.7 is additive. An arrangement can satisfy every clause of section 1191 — no interference with clinical judgment, no control over the listed powers, no offending covenants — and remain unlawful because an unlicensed person holds shares in the professional corporation contrary to section 2408, or because the overall allocation of control offends section 2400 on the older and broader test.

AB 1415 is a notice and data regime. Notice regimes do not authorise the transactions they capture. Filing a complete and timely notice with OHCA is not a determination that the resulting structure complies with the corporate practice doctrine, and nothing in section 127507 says otherwise.

The coverage of Division 1.7 is also narrower than the doctrine it sits beneath. It binds private equity groups and hedge funds as defined in section 1190. A lay individual who owns a clinic outright is not a private equity group, is not a hedge fund, and is entirely outside Division 1.7 — while being squarely inside section 2400, which is where the Medical Board has been bringing those cases all along.

Questions worth asking from inside the practice

These are the transactional questions, and they are answered by documents rather than by reassurance.

What am I actually signing, and how many instruments are there? An acquisition of this kind typically produces an asset purchase agreement, a management services agreement, an employment agreement, and a stock transfer restriction agreement. The employment agreement is the one physicians are given time to read. The transfer restriction agreement determines what happens to the practice, and it is frequently presented as a formality.

On what triggers can I be required to give up the shares, and to whom? Identify the trigger list, who nominates the transferee, and what consideration is payable. If the answer is that the MSO nominates and the price is nominal, the shareholding is custodial.

Which decisions require my approval, and what happens if I withhold it? Section 1191(h) conditions the safe harbour on the clinician retaining ultimate responsibility or approval. Deemed-approval provisions, short response windows, and approval rights held by a physician who can be replaced under the transfer agreement are the mechanics by which an approval right becomes a formality.

Do any terms set patient volume or working hours? Those sit in section 1191(a)(1), where there is no safe harbour, and they frequently appear in a compensation schedule or an operating-metric annexe rather than in the body of an agreement.

Was notice given to OHCA, and when? If the transaction falls within the amended section 127507 and no notice was filed, that is a live compliance question about the transaction itself, distinct from anything in the structure.

What survives if I leave? Competition and non-disparagement clauses in the management and asset-sale documents are void under section 1191(d). Whether the counterparty accepts that, and whether the documents have been revised since January 2026, are separate questions from what the statute says.

What this page does not decide

First, it states California law on ownership, control and transaction notice. It does not address the federal and state fraud-and-abuse regimes — the anti-kickback statute, the physician self-referral rules, and the False Claims Act theories that attach derivatively to non-compliant structures. Those are separate analyses with separate elements, and a structure can fail them while satisfying everything discussed here.

Second, no judicial construction of Division 1.7 is cited, because none was verified as at 16 August 2026. The statute has been operative since 1 January 2026. The 2026 enforcement activity described above rests on the pre-existing corporate practice doctrine rather than on Division 1.7, and settlements resolve claims without adjudicating them. How a court will read “primarily engage in the raising or returning of capital” in section 1190(b), or where assisting under section 1191(h) ends and controlling under section 1191(a)(2) begins, is not resolved by the text alone.

Third, the status of the OHCA regulations proposed on 15 May 2026 is unverified here and should be confirmed with the office before any transaction is timed against it.

Fourth, this page describes structures in general terms. Whether a particular management services agreement offends section 1191 is a question about that document, and the analysis turns on specific clauses rather than on the model.

Sources

1. Cal. Health & Safety Code Division 1.7 — § 1190 (definitions), § 1191 (prohibitions at (a), corporate form at (b), contracting and voidness at (c), restrictive covenants and savings at (d), Attorney General enforcement at (e), purpose at (f), non-abrogation at (g), safe harbour at (h)) and § 1192 (severability) — added by SB 351 (Cabaldon), Chapter 409, Statutes of 2025, chaptered text; approved and filed 6 October 2025; operative 1 January 2026.
2. AB 1415 (Bonta), Chapter 641, Statutes of 2025, chaptered text — an act to amend Health & Safety Code §§ 127500.2, 127501 and 127507, and to add § 127501.5; approved and filed 11 October 2025; effective 1 January 2026.
3. California Office of Health Care Affordability, AB 1415 Frequently Asked Questions — noticing entities must provide written notice under § 127507(c)(2)(A) pending regulations; noticing-entity definitions at § 127507(h)(1)–(h)(4); 90-day filing under § 127507(c)(2) and Cal. Code Regs. tit. 22, § 97435(a).
4. Cal. Bus. & Prof. Code § 2408 and Cal. Corp. Code § 13401.5 — licensed-person requirement for shareholders, directors and officers; 49 per cent cap and headcount limit for listed allied licensees.
5. Cal. Bus. & Prof. Code § 2400 — corporations and other artificial legal entities have no professional rights, privileges or powers.
6. California Department of Justice, Office of the Attorney General — settlement with Carbon Health Technologies, Inc., its affiliated medical groups and its co-founder and former CEO, announced 26 June 2026, subject to court approval.
7. California Department of Justice, Office of the Attorney General — settlement with Aspen Dental Management, Inc. over the corporate practice of dentistry and false advertising, announced 7 May 2026, subject to court approval.
8. Art Center Holdings, Inc. v. WCE CA Art, LLC, California Court of Appeal, Second Appellate District — amicus curiae brief of the California Attorney General filed 30 March 2026. Appeal pending; the brief was not read at source for this page.
9. California Office of Health Care Affordability — proposed emergency regulations implementing AB 1415 published 15 May 2026; informal comment period closed 11 June 2026; board meeting 24 June 2026. Office of Administrative Law approval not verified as at 16 August 2026.
10. Cal. Health & Safety Code § 1250, Cal. Corp. Code § 150, Cal. Gov. Code § 6500 — cross-referenced inside the § 1190 covered-entity exclusions. Cal. Bus. & Prof. Code § 16600 — referenced for contrast only; treated on restrictive covenants. Not read at source for this page.
11. Medical Board of California, Enforcement Actions re Unlicensed Corporate Practice of Medicine — indicators of unlawful corporate practice, including restrictions on the physician’s ability to vote, sell or transfer shares.

Related analysis

• The Corporate Practice of Medicine Doctrine in California
• Restrictive covenants in California physician employment
• Who controls clinical judgment
• Fee splitting and referral payment restrictions
• Hospital consolidation and antitrust enforcement